Ontology type: schema:ScholarlyArticle Open Access: True
2022-04-15
AUTHORSShinya Furukawa, Teruki Miyake, Hiroaki Miyaoka, Bunzo Matsuura, Yoichi Hiasa
ABSTRACTIntroductionLuseogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Unhealthy eating behavior is associated with diabetes, hypertension, and obesity. However, evidence regarding the effect of medications, including SGLT2 inhibitors, on unhealthy eating behavior is limited. This study investigated the association between unhealthy eating behavior and the laboratory and physical findings of Japanese patients with type 2 diabetes given luseogliflozin once daily for 24 weeks.MethodsTwenty-nine patients with type 2 diabetes mellitus were enrolled in a 24-week prospective, open-label, single-arm pilot study. The information regarding unhealthy eating behaviors (eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full) was obtained using self-reported questionnaires.ResultsThe baseline rate of eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full was 51.7%, 24.1%, 24.1%, 10.3% and 55.2%, respectively. After administration of luseogliflozin, fasting plasma glucose, HbA1c, aspartate aminotransferase (ALT), weight, body mass index, and waist measurement all decreased significantly. High-density lipoprotein cholesterol and hematocrit increased significantly. In the healthy eating behavior group, the improvements of fasting plasma glucose and ALT, but not other variables, were attenuated. HbA1c level was significantly improved in patients with eating fast, while other unhealthy eating behaviors attenuated the effect of luseogliflozin for HbA1c. The effect of leseogliflozin on the relationship between eating behavior and weight reduction was inconsistent after administration luseogliflozin.ConclusionLuseogliflozin might be more effective for controlling plasma glucose in patients with type 2 diabetes who have a tendency to eat fast, but it might have less effect on those with other unhealthy eating habits. More... »
PAGES1073-1082
http://scigraph.springernature.com/pub.10.1007/s13300-022-01261-9
DOIhttp://dx.doi.org/10.1007/s13300-022-01261-9
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1147145793
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/35426601
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Health Services Center, Ehime University, Bunkyo, 790-8577, Matsuyama, Ehime, Japan",
"id": "http://www.grid.ac/institutes/grid.255464.4",
"name": [
"Health Services Center, Ehime University, Bunkyo, 790-8577, Matsuyama, Ehime, Japan"
],
"type": "Organization"
},
"familyName": "Furukawa",
"givenName": "Shinya",
"id": "sg:person.0644725370.29",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644725370.29"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan",
"id": "http://www.grid.ac/institutes/grid.255464.4",
"name": [
"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan"
],
"type": "Organization"
},
"familyName": "Miyake",
"givenName": "Teruki",
"id": "sg:person.01322775103.66",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322775103.66"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Internal Medicine, Saiseikei Matusyama Hospital, Matsuyama, Ehime, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Internal Medicine, Saiseikei Matusyama Hospital, Matsuyama, Ehime, Japan"
],
"type": "Organization"
},
"familyName": "Miyaoka",
"givenName": "Hiroaki",
"id": "sg:person.0625744560.75",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625744560.75"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Internal Medicine, Saiseikei Matusyama Hospital, Matsuyama, Ehime, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Internal Medicine, Saiseikei Matusyama Hospital, Matsuyama, Ehime, Japan"
],
"type": "Organization"
},
"familyName": "Matsuura",
"givenName": "Bunzo",
"id": "sg:person.0607425152.67",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607425152.67"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Lifestyle-Related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Japan",
"id": "http://www.grid.ac/institutes/grid.255464.4",
"name": [
"Department of Lifestyle-Related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Japan"
],
"type": "Organization"
},
"familyName": "Hiasa",
"givenName": "Yoichi",
"id": "sg:person.01333031252.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333031252.69"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/s13690-016-0130-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004781331",
"https://doi.org/10.1186/s13690-016-0130-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12325-016-0350-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003457836",
"https://doi.org/10.1007/s12325-016-0350-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00125-012-2746-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046744549",
"https://doi.org/10.1007/s00125-012-2746-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ijo.2015.96",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015739333",
"https://doi.org/10.1038/ijo.2015.96"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.ijo.0802425",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005400823",
"https://doi.org/10.1038/sj.ijo.0802425"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s13300-018-0366-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1100290978",
"https://doi.org/10.1007/s13300-018-0366-8"
],
"type": "CreativeWork"
}
],
"datePublished": "2022-04-15",
"datePublishedReg": "2022-04-15",
"description": "IntroductionLuseogliflozin is a sodium-glucose cotransporter\u00a02 (SGLT2) inhibitor. Unhealthy eating behavior is associated with diabetes, hypertension, and obesity. However, evidence regarding the effect of medications, including SGLT2 inhibitors, on unhealthy eating behavior is limited. This study investigated the association between unhealthy eating behavior and the laboratory and physical findings of Japanese patients with type 2 diabetes given luseogliflozin once daily for 24\u00a0weeks.MethodsTwenty-nine patients with type 2 diabetes mellitus were enrolled in a 24-week prospective, open-label, single-arm pilot study. The information regarding unhealthy eating behaviors (eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full) was obtained using self-reported questionnaires.ResultsThe baseline rate of eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full was 51.7%, 24.1%, 24.1%, 10.3% and 55.2%, respectively. After administration of luseogliflozin, fasting plasma glucose, HbA1c, aspartate aminotransferase (ALT), weight, body mass index, and waist measurement all decreased significantly. High-density lipoprotein cholesterol and hematocrit increased significantly. In the healthy eating behavior group, the improvements of fasting plasma glucose and ALT, but not other variables, were attenuated. HbA1c level was significantly improved in patients with eating fast, while other unhealthy eating behaviors attenuated the effect of luseogliflozin for HbA1c. The effect of leseogliflozin on the relationship between eating behavior and weight reduction was inconsistent after administration luseogliflozin.ConclusionLuseogliflozin might be more effective for controlling plasma glucose in patients with type 2 diabetes who have a tendency to eat fast, but it might have less effect on those with other unhealthy eating habits.",
"genre": "article",
"id": "sg:pub.10.1007/s13300-022-01261-9",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1044057",
"issn": [
"1869-6953",
"1869-6961"
],
"name": "Diabetes Therapy",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "5",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "13"
}
],
"keywords": [
"type 2 diabetes",
"plasma glucose",
"sodium-glucose cotransporter 2 inhibitors",
"high-density lipoprotein cholesterol",
"type 2 diabetes mellitus",
"single-arm pilot study",
"effect of luseogliflozin",
"MethodsTwenty-nine patients",
"cotransporter 2 inhibitors",
"body mass index",
"effects of medication",
"sodium-glucose cotransporter",
"unhealthy eating habits",
"nighttime snack",
"lipoprotein cholesterol",
"diabetes mellitus",
"SGLT2 inhibitors",
"mass index",
"physical findings",
"skipping breakfast",
"Japanese patients",
"waist measurement",
"observational study",
"unhealthy eating behaviours",
"self-report questionnaires",
"luseogliflozin",
"patients",
"aspartate aminotransferase",
"eating habits",
"late dinner",
"diabetes",
"pilot study",
"baseline rate",
"eating behaviors",
"weight reduction",
"behavior groups",
"inhibitors",
"glucose",
"hypertension",
"HbA1c",
"mellitus",
"medications",
"obesity",
"less effect",
"hematocrit",
"breakfast",
"ALT",
"study",
"cholesterol",
"administration",
"aminotransferase",
"weeks",
"effect",
"cotransporter",
"association",
"snacks",
"unhealthy",
"questionnaire",
"dinner",
"group",
"findings",
"habits",
"evidence",
"index",
"levels",
"weight",
"rate",
"reduction",
"improvement",
"Ehime",
"laboratory",
"variables",
"relationship",
"tendency",
"behavior",
"information",
"measurements"
],
"name": "Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study",
"pagination": "1073-1082",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1147145793"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s13300-022-01261-9"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"35426601"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s13300-022-01261-9",
"https://app.dimensions.ai/details/publication/pub.1147145793"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:12",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_937.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s13300-022-01261-9"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01261-9'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01261-9'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01261-9'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01261-9'
This table displays all metadata directly associated to this object as RDF triples.
197 TRIPLES
21 PREDICATES
108 URIs
94 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s13300-022-01261-9 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1103 |
3 | ″ | schema:author | N3e787f8b7e054bd4b8fb9c2951e7fb92 |
4 | ″ | schema:citation | sg:pub.10.1007/s00125-012-2746-3 |
5 | ″ | ″ | sg:pub.10.1007/s12325-016-0350-5 |
6 | ″ | ″ | sg:pub.10.1007/s13300-018-0366-8 |
7 | ″ | ″ | sg:pub.10.1038/ijo.2015.96 |
8 | ″ | ″ | sg:pub.10.1038/sj.ijo.0802425 |
9 | ″ | ″ | sg:pub.10.1186/s13690-016-0130-3 |
10 | ″ | schema:datePublished | 2022-04-15 |
11 | ″ | schema:datePublishedReg | 2022-04-15 |
12 | ″ | schema:description | IntroductionLuseogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Unhealthy eating behavior is associated with diabetes, hypertension, and obesity. However, evidence regarding the effect of medications, including SGLT2 inhibitors, on unhealthy eating behavior is limited. This study investigated the association between unhealthy eating behavior and the laboratory and physical findings of Japanese patients with type 2 diabetes given luseogliflozin once daily for 24 weeks.MethodsTwenty-nine patients with type 2 diabetes mellitus were enrolled in a 24-week prospective, open-label, single-arm pilot study. The information regarding unhealthy eating behaviors (eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full) was obtained using self-reported questionnaires.ResultsThe baseline rate of eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full was 51.7%, 24.1%, 24.1%, 10.3% and 55.2%, respectively. After administration of luseogliflozin, fasting plasma glucose, HbA1c, aspartate aminotransferase (ALT), weight, body mass index, and waist measurement all decreased significantly. High-density lipoprotein cholesterol and hematocrit increased significantly. In the healthy eating behavior group, the improvements of fasting plasma glucose and ALT, but not other variables, were attenuated. HbA1c level was significantly improved in patients with eating fast, while other unhealthy eating behaviors attenuated the effect of luseogliflozin for HbA1c. The effect of leseogliflozin on the relationship between eating behavior and weight reduction was inconsistent after administration luseogliflozin.ConclusionLuseogliflozin might be more effective for controlling plasma glucose in patients with type 2 diabetes who have a tendency to eat fast, but it might have less effect on those with other unhealthy eating habits. |
13 | ″ | schema:genre | article |
14 | ″ | schema:isAccessibleForFree | true |
15 | ″ | schema:isPartOf | N3cc240560df84ed088a52fb5eb2ec086 |
16 | ″ | ″ | Nde2479d1ff1c4c598790b63298d720db |
17 | ″ | ″ | sg:journal.1044057 |
18 | ″ | schema:keywords | ALT |
19 | ″ | ″ | Ehime |
20 | ″ | ″ | HbA1c |
21 | ″ | ″ | Japanese patients |
22 | ″ | ″ | MethodsTwenty-nine patients |
23 | ″ | ″ | SGLT2 inhibitors |
24 | ″ | ″ | administration |
25 | ″ | ″ | aminotransferase |
26 | ″ | ″ | aspartate aminotransferase |
27 | ″ | ″ | association |
28 | ″ | ″ | baseline rate |
29 | ″ | ″ | behavior |
30 | ″ | ″ | behavior groups |
31 | ″ | ″ | body mass index |
32 | ″ | ″ | breakfast |
33 | ″ | ″ | cholesterol |
34 | ″ | ″ | cotransporter |
35 | ″ | ″ | cotransporter 2 inhibitors |
36 | ″ | ″ | diabetes |
37 | ″ | ″ | diabetes mellitus |
38 | ″ | ″ | dinner |
39 | ″ | ″ | eating behaviors |
40 | ″ | ″ | eating habits |
41 | ″ | ″ | effect |
42 | ″ | ″ | effect of luseogliflozin |
43 | ″ | ″ | effects of medication |
44 | ″ | ″ | evidence |
45 | ″ | ″ | findings |
46 | ″ | ″ | glucose |
47 | ″ | ″ | group |
48 | ″ | ″ | habits |
49 | ″ | ″ | hematocrit |
50 | ″ | ″ | high-density lipoprotein cholesterol |
51 | ″ | ″ | hypertension |
52 | ″ | ″ | improvement |
53 | ″ | ″ | index |
54 | ″ | ″ | information |
55 | ″ | ″ | inhibitors |
56 | ″ | ″ | laboratory |
57 | ″ | ″ | late dinner |
58 | ″ | ″ | less effect |
59 | ″ | ″ | levels |
60 | ″ | ″ | lipoprotein cholesterol |
61 | ″ | ″ | luseogliflozin |
62 | ″ | ″ | mass index |
63 | ″ | ″ | measurements |
64 | ″ | ″ | medications |
65 | ″ | ″ | mellitus |
66 | ″ | ″ | nighttime snack |
67 | ″ | ″ | obesity |
68 | ″ | ″ | observational study |
69 | ″ | ″ | patients |
70 | ″ | ″ | physical findings |
71 | ″ | ″ | pilot study |
72 | ″ | ″ | plasma glucose |
73 | ″ | ″ | questionnaire |
74 | ″ | ″ | rate |
75 | ″ | ″ | reduction |
76 | ″ | ″ | relationship |
77 | ″ | ″ | self-report questionnaires |
78 | ″ | ″ | single-arm pilot study |
79 | ″ | ″ | skipping breakfast |
80 | ″ | ″ | snacks |
81 | ″ | ″ | sodium-glucose cotransporter |
82 | ″ | ″ | sodium-glucose cotransporter 2 inhibitors |
83 | ″ | ″ | study |
84 | ″ | ″ | tendency |
85 | ″ | ″ | type 2 diabetes |
86 | ″ | ″ | type 2 diabetes mellitus |
87 | ″ | ″ | unhealthy |
88 | ″ | ″ | unhealthy eating behaviours |
89 | ″ | ″ | unhealthy eating habits |
90 | ″ | ″ | variables |
91 | ″ | ″ | waist measurement |
92 | ″ | ″ | weeks |
93 | ″ | ″ | weight |
94 | ″ | ″ | weight reduction |
95 | ″ | schema:name | Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study |
96 | ″ | schema:pagination | 1073-1082 |
97 | ″ | schema:productId | N717d61a9ee614f739994fa2faec0c53c |
98 | ″ | ″ | Naafe18c5513a449cb01cbf4a9a3b5fa7 |
99 | ″ | ″ | Nd194db754881495ca987022bce705062 |
100 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1147145793 |
101 | ″ | ″ | https://doi.org/10.1007/s13300-022-01261-9 |
102 | ″ | schema:sdDatePublished | 2022-08-04T17:12 |
103 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
104 | ″ | schema:sdPublisher | N61974fe3bba94d088623b2663c8b5289 |
105 | ″ | schema:url | https://doi.org/10.1007/s13300-022-01261-9 |
106 | ″ | sgo:license | sg:explorer/license/ |
107 | ″ | sgo:sdDataset | articles |
108 | ″ | rdf:type | schema:ScholarlyArticle |
109 | N12f3538f92dc494b908020e52409181c | rdf:first | sg:person.01333031252.69 |
110 | ″ | rdf:rest | rdf:nil |
111 | N3cc240560df84ed088a52fb5eb2ec086 | schema:issueNumber | 5 |
112 | ″ | rdf:type | schema:PublicationIssue |
113 | N3e787f8b7e054bd4b8fb9c2951e7fb92 | rdf:first | sg:person.0644725370.29 |
114 | ″ | rdf:rest | N76f32f2b91a74b7c982d442bcb09a163 |
115 | N61974fe3bba94d088623b2663c8b5289 | schema:name | Springer Nature - SN SciGraph project |
116 | ″ | rdf:type | schema:Organization |
117 | N6647e9ec32ca486aafd9647cd47a2293 | rdf:first | sg:person.0607425152.67 |
118 | ″ | rdf:rest | N12f3538f92dc494b908020e52409181c |
119 | N717d61a9ee614f739994fa2faec0c53c | schema:name | pubmed_id |
120 | ″ | schema:value | 35426601 |
121 | ″ | rdf:type | schema:PropertyValue |
122 | N76f32f2b91a74b7c982d442bcb09a163 | rdf:first | sg:person.01322775103.66 |
123 | ″ | rdf:rest | Nb0dfec3d93564a24a2b599357deaae17 |
124 | Naafe18c5513a449cb01cbf4a9a3b5fa7 | schema:name | dimensions_id |
125 | ″ | schema:value | pub.1147145793 |
126 | ″ | rdf:type | schema:PropertyValue |
127 | Nb0dfec3d93564a24a2b599357deaae17 | rdf:first | sg:person.0625744560.75 |
128 | ″ | rdf:rest | N6647e9ec32ca486aafd9647cd47a2293 |
129 | Nd194db754881495ca987022bce705062 | schema:name | doi |
130 | ″ | schema:value | 10.1007/s13300-022-01261-9 |
131 | ″ | rdf:type | schema:PropertyValue |
132 | Nde2479d1ff1c4c598790b63298d720db | schema:volumeNumber | 13 |
133 | ″ | rdf:type | schema:PublicationVolume |
134 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
135 | ″ | schema:name | Medical and Health Sciences |
136 | ″ | rdf:type | schema:DefinedTerm |
137 | anzsrc-for:1103 | schema:inDefinedTermSet | anzsrc-for: |
138 | ″ | schema:name | Clinical Sciences |
139 | ″ | rdf:type | schema:DefinedTerm |
140 | sg:journal.1044057 | schema:issn | 1869-6953 |
141 | ″ | ″ | 1869-6961 |
142 | ″ | schema:name | Diabetes Therapy |
143 | ″ | schema:publisher | Springer Nature |
144 | ″ | rdf:type | schema:Periodical |
145 | sg:person.01322775103.66 | schema:affiliation | grid-institutes:grid.255464.4 |
146 | ″ | schema:familyName | Miyake |
147 | ″ | schema:givenName | Teruki |
148 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322775103.66 |
149 | ″ | rdf:type | schema:Person |
150 | sg:person.01333031252.69 | schema:affiliation | grid-institutes:grid.255464.4 |
151 | ″ | schema:familyName | Hiasa |
152 | ″ | schema:givenName | Yoichi |
153 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333031252.69 |
154 | ″ | rdf:type | schema:Person |
155 | sg:person.0607425152.67 | schema:affiliation | grid-institutes:None |
156 | ″ | schema:familyName | Matsuura |
157 | ″ | schema:givenName | Bunzo |
158 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607425152.67 |
159 | ″ | rdf:type | schema:Person |
160 | sg:person.0625744560.75 | schema:affiliation | grid-institutes:None |
161 | ″ | schema:familyName | Miyaoka |
162 | ″ | schema:givenName | Hiroaki |
163 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625744560.75 |
164 | ″ | rdf:type | schema:Person |
165 | sg:person.0644725370.29 | schema:affiliation | grid-institutes:grid.255464.4 |
166 | ″ | schema:familyName | Furukawa |
167 | ″ | schema:givenName | Shinya |
168 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644725370.29 |
169 | ″ | rdf:type | schema:Person |
170 | sg:pub.10.1007/s00125-012-2746-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1046744549 |
171 | ″ | ″ | https://doi.org/10.1007/s00125-012-2746-3 |
172 | ″ | rdf:type | schema:CreativeWork |
173 | sg:pub.10.1007/s12325-016-0350-5 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1003457836 |
174 | ″ | ″ | https://doi.org/10.1007/s12325-016-0350-5 |
175 | ″ | rdf:type | schema:CreativeWork |
176 | sg:pub.10.1007/s13300-018-0366-8 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1100290978 |
177 | ″ | ″ | https://doi.org/10.1007/s13300-018-0366-8 |
178 | ″ | rdf:type | schema:CreativeWork |
179 | sg:pub.10.1038/ijo.2015.96 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1015739333 |
180 | ″ | ″ | https://doi.org/10.1038/ijo.2015.96 |
181 | ″ | rdf:type | schema:CreativeWork |
182 | sg:pub.10.1038/sj.ijo.0802425 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1005400823 |
183 | ″ | ″ | https://doi.org/10.1038/sj.ijo.0802425 |
184 | ″ | rdf:type | schema:CreativeWork |
185 | sg:pub.10.1186/s13690-016-0130-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1004781331 |
186 | ″ | ″ | https://doi.org/10.1186/s13690-016-0130-3 |
187 | ″ | rdf:type | schema:CreativeWork |
188 | grid-institutes:None | schema:alternateName | Department of Internal Medicine, Saiseikei Matusyama Hospital, Matsuyama, Ehime, Japan |
189 | ″ | schema:name | Department of Internal Medicine, Saiseikei Matusyama Hospital, Matsuyama, Ehime, Japan |
190 | ″ | rdf:type | schema:Organization |
191 | grid-institutes:grid.255464.4 | schema:alternateName | Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan |
192 | ″ | ″ | Department of Lifestyle-Related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Japan |
193 | ″ | ″ | Health Services Center, Ehime University, Bunkyo, 790-8577, Matsuyama, Ehime, Japan |
194 | ″ | schema:name | Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan |
195 | ″ | ″ | Department of Lifestyle-Related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Japan |
196 | ″ | ″ | Health Services Center, Ehime University, Bunkyo, 790-8577, Matsuyama, Ehime, Japan |
197 | ″ | rdf:type | schema:Organization |